Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P11279
UPID:
LAMP1_HUMAN
Alternative names:
CD107 antigen-like family member A
Alternative UPACC:
P11279; B4DWL3; Q8WU33; Q96I40; Q9BRD2; Q9NP13
Background:
Lysosome-associated membrane glycoprotein 1 (LAMP-1), also known as CD107 antigen-like family member A, is pivotal in lysosome biogenesis, autophagy, and cholesterol homeostasis. It enhances NK-cells' cytotoxicity by facilitating cytotoxic granule movement and perforin trafficking, while also protecting NK-cells from their own cytotoxic granules. LAMP-1 serves as a receptor for Lassa virus and aids in mumps virus fusion through interaction with FURIN and the mumps virus fusion protein F.
Therapeutic significance:
Understanding the role of Lysosome-associated membrane glycoprotein 1 could open doors to potential therapeutic strategies.